BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, January 25, 2025
See today's BioWorld MedTech
See today's BioWorld
Home
» Nanology aims to tackle hypoxic cancer tumors with nano-scale drug delivery tech
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Nanology aims to tackle hypoxic cancer tumors with nano-scale drug delivery tech
June 11, 2021
By
David Godkin
No Comments
TORONTO – Nanology Labs Inc. has raised C$3 million (US$2.49 million) in seed funding to advance development of a polymer-lipid platform that transports nanoparticles into human cells where they “reprogram” hypoxic or oxygen-deprived cancer tumors.
BioWorld
BioWorld MedTech
Financings
Cancer
Seed
Canada